Hospital Jerez Puerta Del Sur Grupo Hla S.A.

The oncology team at Hospital Jerez Puerta Del Sur Grupo Hla S.A. is evaluating a new nivolumab biosimilar for patients who have undergone resection for stage IIB, IIC, or III melanoma and require adjuvant therapy. The goal is to determine whether the biosimilar can provide comparable effectiveness to the established treatment while offering potential benefits in accessibility.

• Comparative effectiveness of the biosimilar versus reference immunotherapy
• Safety and tolerability in the postoperative setting
• Monitoring of disease‑free survival and recurrence rates

With four investigators leading the effort, this work aims to improve clinical outcomes and expand treatment options for melanoma patients across Europe.

In the respiratory unit, researchers are testing metoprolol as a novel approach to treat Acute Respiratory Distress Syndrome (ARDS). The trial focuses on increasing the number of days alive and free of invasive mechanical ventilation within the first 28 days, seeking to reduce the burden of prolonged ventilation.

• Evaluation of beta‑blocker impact on lung inflammation
• Reduction of duration of invasive ventilation
• Early safety and hemodynamic monitoring

Conducted by a team of four investigators, the study strives to demonstrate a meaningful clinical benefit for patients facing severe respiratory failure.